Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vlad Ratziu

Showing results (21-30 of 384) with videos related to

Pageof 39
Sort By:
Hepatology (Baltimore, Md.)|June 17, 2023
Reply: More questions than answers-Response to the POP-NEXT projectVlad Ratziu, Nancy Reau
Nature Clinical Practice. Gastroenterology & Hepatology|November 3, 2005
Long-term outcome improvement in patients with chronic hepatitis D treated with interferon alphaVlad Ratziu, Thierry Poynard
Journal of Hepatology|July 16, 2023
At the dawn of potent therapeutics for fatty liver disease - introducing the miniseries on promising pharmacological targets for NASHVlad Ratziu, Frank Tacke
Hepatology International|July 24, 2015
Pharmacological agents for nonalcoholic steatohepatitisMaeva Guillaume, Vlad Ratziu
Journal of Hepatology|August 5, 2023
Confirmatory biomarker diagnostic studies are not needed when transitioning from NAFLD to MASLDVlad Ratziu, Jérôme Boursier,
Journal of Hepatology|January 17, 2025
The Journal of Hepatology: A new team at 40Vlad Ratziu, Frank Tacke
Journal of Hepatology|January 5, 2005
NASH: a hidden and silent fibroser finally revealed?Vlad Ratziu, Thierry Poynard
Clinics in Liver Disease|April 6, 2023
Future Treatment Options and Regimens for Nonalcoholic Fatty Liver DiseaseSven Francque, Vlad Ratziu
Journal of Hepatology|June 21, 2016
When the journey from obesity to cirrhosis takes an early startVlad Ratziu, Giulio Marchesini
Journal of Hepatology|August 8, 2016
Reply to "Establishing the independence and clinical importance of non-alcoholic fatty liver disease as a risk factor for cardiovascular disease"Raluca Pais, Vlad Ratziu
Pageof 39

Showing results (21-30 of 384) with videos related to

Sort By:
Pageof 39
Hepatology (Baltimore, Md.)|June 17, 2023
Reply: More questions than answers-Response to the POP-NEXT projectVlad Ratziu, Nancy Reau
Nature Clinical Practice. Gastroenterology & Hepatology|November 3, 2005
Long-term outcome improvement in patients with chronic hepatitis D treated with interferon alphaVlad Ratziu, Thierry Poynard
Journal of Hepatology|July 16, 2023
At the dawn of potent therapeutics for fatty liver disease - introducing the miniseries on promising pharmacological targets for NASHVlad Ratziu, Frank Tacke
Hepatology International|July 24, 2015
Pharmacological agents for nonalcoholic steatohepatitisMaeva Guillaume, Vlad Ratziu
Journal of Hepatology|August 5, 2023
Confirmatory biomarker diagnostic studies are not needed when transitioning from NAFLD to MASLDVlad Ratziu, Jérôme Boursier,
Journal of Hepatology|January 17, 2025
The Journal of Hepatology: A new team at 40Vlad Ratziu, Frank Tacke
Journal of Hepatology|January 5, 2005
NASH: a hidden and silent fibroser finally revealed?Vlad Ratziu, Thierry Poynard
Clinics in Liver Disease|April 6, 2023
Future Treatment Options and Regimens for Nonalcoholic Fatty Liver DiseaseSven Francque, Vlad Ratziu
Journal of Hepatology|June 21, 2016
When the journey from obesity to cirrhosis takes an early startVlad Ratziu, Giulio Marchesini
Journal of Hepatology|August 8, 2016
Reply to "Establishing the independence and clinical importance of non-alcoholic fatty liver disease as a risk factor for cardiovascular disease"Raluca Pais, Vlad Ratziu
Pageof 39